SG11202000840YA - Cellular models of and therapies for ocular diseases - Google Patents
Cellular models of and therapies for ocular diseasesInfo
- Publication number
- SG11202000840YA SG11202000840YA SG11202000840YA SG11202000840YA SG11202000840YA SG 11202000840Y A SG11202000840Y A SG 11202000840YA SG 11202000840Y A SG11202000840Y A SG 11202000840YA SG 11202000840Y A SG11202000840Y A SG 11202000840YA SG 11202000840Y A SG11202000840Y A SG 11202000840YA
- Authority
- SG
- Singapore
- Prior art keywords
- therapies
- ocular diseases
- cellular models
- models
- cellular
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
- 230000001413 cellular effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/80—Cytochromes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762539473P | 2017-07-31 | 2017-07-31 | |
PCT/IB2018/055755 WO2019025984A1 (en) | 2017-07-31 | 2018-07-31 | CELLULAR MODELS AND THERAPIES FOR OCULAR DISEASES |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000840YA true SG11202000840YA (en) | 2020-02-27 |
Family
ID=65232366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000840YA SG11202000840YA (en) | 2017-07-31 | 2018-07-31 | Cellular models of and therapies for ocular diseases |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200255859A1 (zh) |
EP (1) | EP3662066B1 (zh) |
JP (2) | JP7448953B2 (zh) |
KR (1) | KR20200036912A (zh) |
CN (1) | CN111630170A (zh) |
AU (1) | AU2018311504A1 (zh) |
BR (1) | BR112020001940A2 (zh) |
CA (1) | CA3071769A1 (zh) |
IL (1) | IL272339B2 (zh) |
MX (1) | MX2020001340A (zh) |
NZ (1) | NZ761655A (zh) |
SG (1) | SG11202000840YA (zh) |
TW (1) | TWI820034B (zh) |
WO (1) | WO2019025984A1 (zh) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
KR102465067B1 (ko) * | 2018-02-15 | 2022-11-10 | 시그마-알드리치 컴퍼니., 엘엘씨 | 진핵 게놈 변형을 위한 조작된 cas9 시스템 |
BR112020020266A2 (pt) | 2018-04-03 | 2021-01-19 | Stridebio, Inc. | Vetores de vírus com evasão de anticorpos |
AU2019255708A1 (en) | 2018-04-17 | 2020-11-26 | Ascidian Therapeutics, Inc. | Trans-splicing molecules |
AU2020221274B2 (en) | 2019-02-15 | 2024-02-08 | Sigma-Aldrich Co. Llc. | Crispr/Cas fusion proteins and systems |
MX2021010149A (es) * | 2019-02-25 | 2021-09-14 | Novartis Ag | Composiciones y metodos para tratar la distrofia cristalina de bietti. |
US20220154211A1 (en) * | 2019-02-25 | 2022-05-19 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
CA3131919A1 (en) * | 2019-02-28 | 2020-09-03 | Regeneron Pharmaceuticals, Inc. | Adeno-associated virus vectors for the delivery of therapeutics |
CA3133453A1 (en) | 2019-03-21 | 2020-09-24 | Daniel Mccoy | Recombinant adeno-associated virus vectors |
CN109979539B (zh) * | 2019-04-10 | 2020-10-02 | 电子科技大学 | 基因序列优化方法、装置及数据处理终端 |
AU2020328511A1 (en) | 2019-08-09 | 2022-03-03 | Nutcracker Therapeutics, Inc. | Methods and apparatuses for manufacturing for removing material from a therapeutic composition |
JP2022546236A (ja) * | 2019-08-14 | 2022-11-04 | ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. | 遺伝子治療のためのaavカプシドバリアント |
CN110684737B (zh) * | 2019-08-29 | 2021-06-18 | 中山大学中山眼科中心 | 一种rpe65基因突变患者的诱导多能干细胞 |
BR112022006530A2 (pt) * | 2019-10-17 | 2022-07-05 | Stridebio Inc | Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c |
US20240131185A1 (en) * | 2019-10-17 | 2024-04-25 | Stridebio, Inc. | Aav transfer cassette |
WO2021114662A1 (zh) * | 2019-12-09 | 2021-06-17 | 北京大学第三医院(北京大学第三临床医学院) | CYP4V2和RdCVF在制备药物中的用途 |
JP2023513208A (ja) * | 2020-02-07 | 2023-03-30 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | 神経変性の発症を遅延させるかまたは神経変性を処置するためのメタボロームのリプログラミング |
CN111349148A (zh) * | 2020-03-13 | 2020-06-30 | 辉大(上海)生物科技有限公司 | 一种腺相关病毒载体及其用途 |
CN113106124B (zh) * | 2020-06-09 | 2022-09-23 | 北京中因科技有限公司 | 表达cyp4v2的aav载体及其用途 |
CN111500635B (zh) * | 2020-07-02 | 2020-10-09 | 北京大学第三医院(北京大学第三临床医学院) | 一种包含携带核酸分子的载体的试剂盒 |
EP4185335A1 (en) * | 2020-07-21 | 2023-05-31 | Frontera Therapeutics, Inc. | Compositions and methods for the treatment of ocular diseases |
RU2741092C1 (ru) * | 2020-07-23 | 2021-01-22 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кузбасская государственная сельскохозяйственная академия" | Генетическая конструкция для получения устойчивых к вирусу лейкоза эмбрионов крупного рогатого скота |
CN111849998A (zh) * | 2020-07-29 | 2020-10-30 | 武汉纽福斯生物科技有限公司 | 编码人卵黄状黄斑病蛋白1的核酸分子及其应用 |
WO2022021149A1 (zh) * | 2020-07-29 | 2022-02-03 | 北京中因科技有限公司 | Aav介导的rpgr x连锁视网膜变性的基因编辑治疗 |
CN111826378B (zh) * | 2020-08-05 | 2022-05-27 | 武汉纽福斯生物科技有限公司 | 一种编码人受体酪氨酸激酶Mer的核苷酸序列及其应用 |
CN111733174B (zh) * | 2020-08-07 | 2021-02-09 | 北京大学第三医院(北京大学第三临床医学院) | 一种分离的核酸分子及其用途 |
CN113166763B (zh) * | 2020-09-24 | 2022-03-15 | 北京中因科技有限公司 | 靶向cyp4v2基因突变位点的核酸分子及其用途 |
CN113015804B (zh) * | 2020-10-13 | 2022-05-17 | 北京中因科技有限公司 | 用于治疗结晶样视网膜变性的核酸分子及其用途 |
RU2749459C1 (ru) * | 2020-11-10 | 2021-06-11 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Универсальный интеграционный вектор pVEAL и рекомбинантная плазмида pVEAL-15742, обеспечивающая синтез и секрецию scFv-Fc антител ADI-15742 против вируса Эбола в клетках млекопитающих и полученная с использованием вектора pVEAL |
WO2022140551A1 (en) * | 2020-12-23 | 2022-06-30 | The Schepens Eye Research Institute, Inc. | Methods and compositions for the treatment of corneal endothelium disorders |
CN112852871A (zh) * | 2021-01-15 | 2021-05-28 | 西南大学 | 高效编辑家蚕基因组的Cas9系统及其应用 |
GB202104611D0 (en) * | 2021-03-31 | 2021-05-12 | Univ Oxford Innovation Ltd | Gene therapy for retinal disease |
CN113318230B (zh) * | 2021-06-11 | 2022-08-26 | 上海交通大学医学院附属第九人民医院 | Optineurin在眼部黑色素瘤诊治中的应用 |
KR20240052746A (ko) * | 2021-07-14 | 2024-04-23 | 메이라지티엑스 유케이 Ii 리미티드 | Kcnv2 유전자 요법 |
EP4370663A1 (en) * | 2021-07-15 | 2024-05-22 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating bietti crystalline dystrophy |
WO2023140837A1 (en) * | 2022-01-19 | 2023-07-27 | Massachusetts Eye And Ear Infirmary | Optimized aav-based vaccine |
US20230100367A1 (en) * | 2021-08-24 | 2023-03-30 | National Yang Ming Chiao Tung University | Methods of treating cdgsh iron sulfur domain 2 insufficiency-associated disorders |
CN114381465B (zh) * | 2021-12-22 | 2024-01-16 | 苏州诺洁贝生物技术有限公司 | 优化的cyp4v2基因及其用途 |
WO2023147058A2 (en) * | 2022-01-27 | 2023-08-03 | Asklepios Biopharmaceutical, Inc. | Compositions for treating neurological disease |
KR20240000814A (ko) * | 2022-06-24 | 2024-01-03 | 연세대학교 산학협력단 | 망막색소상피에 특이적으로 작동하는 CRISPR/Cas 복합체를 유효성분으로 포함하는 망막질환 치료용 약학조성물 |
WO2024092086A1 (en) * | 2022-10-26 | 2024-05-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regenerating corneal endothelium |
CN116738352B (zh) * | 2023-08-14 | 2023-12-22 | 武汉大学人民医院(湖北省人民医院) | 视网膜血管阻塞疾病的视杆细胞异常分类方法及装置 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5792751A (en) | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
IL128736A0 (en) | 1996-09-06 | 2000-01-31 | Univ Pennsylvania | Methods using cre-lox for production of recombinant adeno-associated viruses |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
CA2304983A1 (en) | 1997-09-24 | 1999-04-01 | The Regents Of The University Of California | Non-primate lentiviral vectors and packaging systems |
US6106826A (en) | 1997-12-17 | 2000-08-22 | Wisconsin Alumni Research Foundation | Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy |
US7122181B2 (en) | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
US7144870B2 (en) | 2002-02-15 | 2006-12-05 | Research Development Foundation | Hyaluronic acid mediated adenoviral transduction |
WO2004023973A2 (en) * | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules for diagnostics and therapeutics |
US8326547B2 (en) | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
US20120108651A1 (en) * | 2010-11-02 | 2012-05-03 | Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
MX362866B (es) | 2012-05-25 | 2019-02-20 | Univ California | Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn. |
EP2692868A1 (en) * | 2012-08-02 | 2014-02-05 | Universitat Autònoma De Barcelona | Adeno-associated viral (AAV) vectors useful for transducing adipose tissue |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
US8993233B2 (en) | 2012-12-12 | 2015-03-31 | The Broad Institute Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
AU2013359212B2 (en) | 2012-12-12 | 2017-01-19 | Massachusetts Institute Of Technology | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
EP2954051B1 (en) * | 2013-02-08 | 2019-03-27 | The Trustees Of The University Of Pennsylvania | Modified aav8 capsid for gene transfer for retinal therapies |
CN103374575B (zh) * | 2013-04-16 | 2015-01-07 | 中国人民解放军第三军医大学第一附属医院 | Cyp4v2基因突变体及其应用 |
CN103374574B (zh) * | 2013-04-16 | 2015-01-07 | 中国人民解放军第三军医大学第一附属医院 | Cyp4v2基因突变体及其应用 |
EP3561062A1 (en) | 2013-09-13 | 2019-10-30 | California Institute of Technology | Selective recovery |
CN103468820B (zh) * | 2013-09-27 | 2015-06-10 | 中国人民解放军第三军医大学 | 检测cyp4v2基因常见突变的试剂盒 |
TN2016000220A1 (en) * | 2013-12-06 | 2017-10-06 | Ct Hospitalier Universitaire Montpellier | Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject. |
CN104745592B (zh) * | 2013-12-31 | 2020-02-21 | 第三军医大学第一附属医院 | Cyp4v2基因突变体及其应用 |
CN104745594B (zh) * | 2013-12-31 | 2019-10-25 | 中国人民解放军第三军医大学第一附属医院 | Cyp4v2基因突变体及其应用 |
CN104745591B (zh) * | 2013-12-31 | 2020-04-03 | 中国人民解放军第三军医大学第一附属医院 | Cyp4v2基因突变体及其应用 |
JP6734853B2 (ja) * | 2014-12-18 | 2020-08-05 | ソルボンヌ・ユニヴェルシテSorbonne Universite | 網膜変性処置のためのotx2過剰発現トランスジェニック網膜色素上皮細胞 |
CA2985223A1 (en) | 2015-05-07 | 2016-11-10 | Massachusetts Eye And Ear Infirmary | Methods of delivering an agent to the eye |
GB201519086D0 (en) * | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
WO2017191274A2 (en) * | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
-
2018
- 2018-07-31 MX MX2020001340A patent/MX2020001340A/es unknown
- 2018-07-31 EP EP18842071.5A patent/EP3662066B1/en active Active
- 2018-07-31 KR KR1020207005930A patent/KR20200036912A/ko not_active Application Discontinuation
- 2018-07-31 BR BR112020001940-2A patent/BR112020001940A2/pt unknown
- 2018-07-31 JP JP2020528530A patent/JP7448953B2/ja active Active
- 2018-07-31 CA CA3071769A patent/CA3071769A1/en active Pending
- 2018-07-31 SG SG11202000840YA patent/SG11202000840YA/en unknown
- 2018-07-31 WO PCT/IB2018/055755 patent/WO2019025984A1/en unknown
- 2018-07-31 IL IL272339A patent/IL272339B2/en unknown
- 2018-07-31 NZ NZ761655A patent/NZ761655A/en unknown
- 2018-07-31 TW TW107126585A patent/TWI820034B/zh active
- 2018-07-31 US US16/635,863 patent/US20200255859A1/en active Pending
- 2018-07-31 AU AU2018311504A patent/AU2018311504A1/en active Pending
- 2018-07-31 CN CN201880064626.5A patent/CN111630170A/zh active Pending
-
2024
- 2024-02-22 JP JP2024025982A patent/JP2024059813A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NZ761655A (en) | 2024-03-22 |
IL272339B1 (en) | 2024-01-01 |
IL272339A (en) | 2020-03-31 |
TWI820034B (zh) | 2023-11-01 |
JP7448953B2 (ja) | 2024-03-13 |
BR112020001940A2 (pt) | 2020-08-18 |
TW201920679A (zh) | 2019-06-01 |
WO2019025984A1 (en) | 2019-02-07 |
IL272339B2 (en) | 2024-05-01 |
CA3071769A1 (en) | 2019-02-07 |
US20200255859A1 (en) | 2020-08-13 |
JP2021500917A (ja) | 2021-01-14 |
KR20200036912A (ko) | 2020-04-07 |
EP3662066B1 (en) | 2024-06-05 |
EP3662066A1 (en) | 2020-06-10 |
AU2018311504A1 (en) | 2020-03-12 |
MX2020001340A (es) | 2020-08-31 |
CN111630170A (zh) | 2020-09-04 |
JP2024059813A (ja) | 2024-05-01 |
EP3662066A4 (en) | 2021-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272339A (en) | Cellular models and treatments for eye diseases | |
HRP20190117T1 (hr) | iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA | |
EP3177732A4 (en) | Compositions and methods for the treatment of ophthalmic diseases and conditions | |
EP3390634A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES | |
IL246791A0 (en) | Compositions and methods for treating eye diseases | |
IL269074A (en) | Proteins that bind anti-TIGIT antigens and methods of using them | |
EP3240612A4 (en) | Methods of treating retinal diseases | |
SG11201708114SA (en) | Ophthalmic compositions and methods of use therefor | |
EP3125971A4 (en) | Internal body cavity therapeutic applicators and methods for using them | |
IL268357A (en) | Photoreceptor cells for the treatment of retinal diseases | |
ZA201906213B (en) | Compounds and methods for the treatment of parasitic diseases | |
EP3503903A4 (en) | ASCAROSIDE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | |
IL269363A (en) | Methods for measuring medical effects of treating retinal diseases | |
EP3515444A4 (en) | COMPOSITION FOR TREATING EYE DISEASES AND METHOD FOR USE AND PRODUCTION | |
IL266720A (en) | Proteins that bind against gitr antigens and methods of using them | |
EP3472181A4 (en) | METHOD FOR DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES | |
EP3713553A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF EYE DISEASES | |
IL269698B (en) | Methods for preventing or treating eye diseases | |
HK1255691A1 (zh) | 對疾病進行組織學診斷和治療的方法 | |
HK1219654A1 (zh) | 用於治療眼科疾病和病症的方法 | |
IL259381B (en) | Miravegron for the treatment of retinal diseases | |
PL3515409T3 (pl) | Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych | |
EP3402511A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | |
PL3151666T3 (pl) | Modele zwierzęce angiogenezy rogówki oraz chorób rozstrzeniowych rogówki, sposoby wytwarzania i sposoby ich zastosowania | |
SG11202005278PA (en) | Compounds for treating eye diseases and methods thereof |